Shots:

• The opinion is based on P-II ELOQUENT-3 study assessing Empliciti (elotuzumab) + pomalidomide and dexamethasone (EPd) vs pomalidomide + dexamethasone (Pd) in 117 patients in a ratio (1:1) with multiple myeloma prior treated with 2L+ therapies including lenalidomide and a proteasome inhibitor
• The CHMP recommendation will be reviewed by the European Commission to approve the combination therapy in the EU. The CHMP’s positive opinion further validates the Empliciti-based combination for patients with MM- r/r to prior therapies
• Empliciti is an immunostimulatory Ab targeting SLAMF7 and has received the US FDA’s approval in combination with lenalidomide and dexamethasone for MM in 2015- co-developed by BMS and AbbVie with BMS being solely responsible for commercialization activities

Click here to­ read full press release/ article

 Ref: BMS | Image: BMS